Receive a free case review.
Elidel (generic name: pimecrolimus) is manufactured and marketed by
Novartis. In December 2001, the FDA approved Elidel to treat eczema, an allergic reaction that causes skin inflammation. Unfortunately, millions of Americans used Elidel not knowing that it was linked to severe side effects, including skin cancer and lymphoma. In January 2006, the FDA ordered Novartis to add a black box warning to Elidel’s label detailing the increased cancer risk.
Elidel Lawsuits: Pre-Emption Ruling
In January 2007, the U.S. District Court for the Eastern District of Pennsylvania ruled against FDA pre-emption in an Elidel lawsuit. The principle of pre-emption mandates that federal law trump state law if federal and state law conflict. Therefore, Novartis, Elidel’s manufacturer, argued that plaintiffs could not file a lawsuit under a failure to warn theory because the FDA did not require warnings for skin cancer and lymphoma
|
Related Topics: |
Elidel New Jersey Lawsuits
Two Elidel lawsuits were filed against Novartis in the Atlantic County Superior Court in New Jersey. In one case, Haley Thomson’s parents filed a wrongful death lawsuit after Haley died from cancer after exposure to Elidel. In the other case, the plaintiff filed a personal injury lawsuit after developing lymphoma, undergoing three surgeries and four months of chemotherapy treatment after using Elidel. Both Elidel lawsuits allege that:
Filing an Elidel Lawsuit
If you would like more information about Elidel lawsuits, or if you or a loved one has developed serious side effects from using Elidel, contact us to discuss your potential lawsuit today. Recovery from a lawsuit may include compensation for:
Pimecrolimus